Smith & Nephew PLC has released its third-quarter trading report, highlighting a revenue growth of 3.4% for the period ending September 26, 2026. This growth is attributed to strong performance in its Sports Medicine and ENT divisions, although the company has revised its full-year guidance due to slower growth in its Orthopaedics segment.

The company, which specializes in orthopedic, prosthetic, and surgical appliances and supplies, filed its report on November 4, 2026, under the SEC's 6-K form. The update is significant as it indicates both the company's current performance and its outlook amid ongoing challenges in the orthopedic market.

Background

Smith & Nephew PLC, listed on the NYSE under the ticker SNN and on the London Stock Exchange as SN, operates in the orthopedic, prosthetic, and surgical appliances and supplies sector (SIC: 3842). The company has a strong presence in the medical technology industry, focusing on innovative solutions for patients and healthcare providers. Recent filings include multiple 6-K forms leading up to the latest report, indicating ongoing communication with investors and stakeholders.

What the Filing Says

The filing reveals that Smith & Nephew's Q3 revenue reached $1,551 million, up from $1,501 million in Q3 2025. The report highlights a notable performance in Sports Medicine, particularly in Joint Repair, which saw double-digit growth. However, the company acknowledged that Orthopaedics, particularly in the US, faced softer market conditions, prompting a revision in its full-year guidance.

Deepak Nath, Chief Executive Officer, stated, "We have revised our full-year guidance to reflect the slower growth in US Orthopaedics, which we expect to continue through the fourth quarter. Despite this, we remain confident in delivering profit growth ahead of revenue growth, together with strong free cash flow and cash conversion."

Impact

This update is likely to affect various stakeholders, including investors, healthcare providers, and competitors in the orthopedic and surgical supplies industry. The revision of growth expectations may prompt investors to reassess their outlook on the company's performance and strategic direction, especially in light of the competitive landscape.

What's Next

The filing does not specify what happens next, but it indicates that Smith & Nephew will continue to focus on improving its Orthopaedics performance and enhancing operational efficiency as part of its RISE strategy.